

## Our Clinical Enterprises

- Christopher Moertel, M.D. and Joseph Neglia, M.D., M.P.H. provide pediatric neuro-oncology care to children and young adults with brain tumors and other nervous system tumors including our growing population of patients in Neurofibromatosis.
- We provide experienced neuro-oncology nursing support for our clinical activities.
- We are part of the Children's Tumor Foundation Neurofibromatosis network.
- We are the only Children's Oncology Group Phase 1 site in Minnesota. This lets us provide experimental therapies to children that until now have only been tested on adults.

## Our Research Collaborations

- University-based investigators with novel therapeutic approaches
- World class magnetic resonance imaging (MRI) research program
- Biomedical Engineering Institute
- Brain Barriers Research Center, Pharmaceutical Department
- Veterinary School support for clinical trials and device development in dogs with brain tumors
- Center for Molecular and Cellular Therapies




## Contact Information

**David Largaespada, Ph.D.**, Brain Tumor Program Director

**email** [larga002@umn.edu](mailto:larga002@umn.edu) **phone** 612-626-4979

**Amy Gaug**, administrative contact

**email** [gaugx002@umn.edu](mailto:gaugx002@umn.edu) **phone** 612-626-2602



## The Children's Cancer Research Fund






The Children's Cancer Research Fund is dedicated to finding a cure for childhood cancer by providing funds to the University of Minnesota for research and training relating to the prevention, treatment and cure of childhood cancer. The organization also educates the public about childhood cancer and supports quality-of-life programs for pediatric cancer patients and their families.


The Children's Cancer Research Fund focuses on supporting pioneering research initiatives that lead to larger studies, clinical trials and improved methods of treating childhood cancer. Ultimately, it will be the breakthroughs in diagnosis and treatment that help prevent childhood cancer. To learn more about the Children's Cancer Research fund, visit their website at [www.childrenscancer.org](http://www.childrenscancer.org).

## The University of Minnesota Masonic Cancer Center

Advancing knowledge, enhancing care is the mission of the University of Minnesota Masonic Cancer Center. This mission is fostered through scientific research on cancer, clinical treatment of patients with cancer and public education about cancer.

The University of Minnesota established the Cancer Center in 1991, and the National Cancer Institute (NCI) designated the University's Cancer Center a "Comprehensive Cancer Center" in 1998 because of its ongoing, significant advances in cancer research, treatment and education. To learn more visit their website at [www.cancer.umn.edu](http://www.cancer.umn.edu).





## The University of Minnesota Brain Tumor Program...

- is a multi-dimensional effort to understand and more effectively treat and cure brain tumors.
- was established by key contributors of the Children's Cancer Research Fund.
- is a developing program of the Masonic Cancer Center.
- is led by Pediatric Hematology/Oncology and Blood and Marrow Transplantation faculty who are experts in neuro-oncology, cellular and immune based therapies and cancer genetics.

## Our Mission

To create one of the nation's leading basic, pre-clinical and translational research programs in neuro-oncology.

## Our Vision

Our vision is to cure brain and other nervous system tumors in children and adults. We are a growing, interactive and engaged group of investigators, all committed to the ultimate goal of delivering less toxic and more effective treatments for nervous system tumors.

This vision can only be realized through the application of multidisciplinary care across the continuum of basic science, clinical investigation and patient focused care delivery. The University of Minnesota Brain Tumor Program is built around the guiding principal of developing ideas based on scientific discoveries that can be transferred through the discovery chain into clinical trials for children and adults. Through this process, new therapies will be developed and delivered in an environment focused on the complete care of the patients and their families.


## Our Leaders



**David Largaespada, Ph.D.** Professor Genetics, Cell Biology and Development and Pediatrics; Leader Genetic Mechanisms of Cancer Program, Masonic Cancer Center. Dr. Largaespada's lab is working to discover new brain cancer genes that will explain brain tumor development and serve as targets for new therapies.



**Chris Moertel, M.D.** Professor Pediatric Hematology/Oncology and BMT; Clinical Director Pediatric Neuro-oncology; Director University of Minnesota Neurocutaneous Syndromes Clinic Without Walls Neurofibromatosis Clinic. Dr. Moertel is working to provide cutting edge therapies for people with brain tumors and neurofibromatosis-related syndromes.



**John Ohlfest, Ph.D.** Assistant Professor Division of Pediatric Hematology/Oncology and BMT and the Department of Neurosurgery. Dr. Ohlfest's research program focuses on brain tumor experimental therapeutics. His team is developing novel drug delivery platforms and more potent anti-tumor vaccines.



**Joseph Neglia, M.D., M.P.H.** Professor Pediatrics; Section Chief Hematology/Oncology and BMT. Dr. Neglia is studying the long-term effects of cancer therapy in cancer survivors and the occurrence of second malignancies following childhood cancers.



**John Wagner, M.D.** Professor and Division Director Pediatric Hematology/Oncology and BMT; Director Molecular and Cellular Therapeutics; Co-leader Transplant Biology and Therapy Research Program; Co-director Center for Translational Medicine. Dr. Wagner develops novel cellular therapies to treat brain tumors and other childhood and adult diseases.

